FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家銀行表示,由於下游業務疲軟拖累獲利,埃尼集團第一季業績喜憂參半。

By

-- 埃尼集團 (Eni) 第一季度業績喜憂參半,盈利低於預期,主要原因是其下游業務疲軟以及維護成本上升。加拿大皇家銀行 (RBC) 在周一發送的電子郵件報告中指出。 分析師表示,儘管業績不佳,但更樂觀的業績指引彌補了這一不足,促使該公司將股票回購計畫從 15 億歐元(17.6 億美元)增加到 28 億歐元。 RBC 表示:“我們原本預期,在宏觀經濟波動的情況下,各公司會保持謹慎,而不是在第一季度堅持按公式派息。然而,埃尼集團率先公佈業績,其管理層已向整個行業發出了挑戰。” 展望未來,RBC 指出,一些潛在的利多因素可能對埃尼集團構成支撐,包括印尼和委內瑞拉的發展(這些發展尚未納入績效指引),這些發展在 2030 年左右可能帶來成長。分析師表示,不利因素在於義大利政府可能進行的配股計畫存在一些不確定性,這可能會影響市場情緒。 分析師表示,他們將2026年每股收益預期調高3%,同時將經營活動現金流預期調降3%。基於更高的油價預期,他們目前預計該公司將進行32億歐元的股票回購,高於公司先前的指引。 RBC維持對埃尼集團(Eni)的「與業界持平」評級,目標價為28歐元。

Price: $53.80, Change: $-0.31, Percent Change: -0.57%

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP